AdvanCell’s ESMO abstract reports favorable safety and early anti-tumor activity for ADVC001, a Lead-212 (212Pb)-labeled PSMA radioligand, across seven Phase 1b dose-escalation cohorts in metastatic castration-resistant prostate cancer. No quantitative efficacy or adverse event rates were disclosed in the abstract, but this is the first clinical dataset for a 212Pb-PSMA therapy to reach a major oncology forum, with updated results slated for presentation.
The core development is an upcoming poster at ESMO 2025 detailing the Phase 1b portion of the TheraPb Phase 1/2 trial in PSMA-positive mCRPC, with data initially cut as of May 9, 2025, and additional cohorts since treated. The dose-finding design evaluates administration every 6, 4, 2, or 1 weeks, ahead of a Phase 2 expansion that will assess recommended doses in mCRPC and metastatic hormone-sensitive prostate cancer with randomization and dose optimization elements. The company emphasizes the short half-life and high dose rate of 212Pb as central to the candidate’s design.
The strategic bet is clear: move PSMA-targeted radioligand therapy beyond beta emitters and into alpha payloads that can deliver higher linear energy transfer and potentially overcome resistance seen post-Lu-177. Opting for 212Pb rather than 225Ac signals a different manufacturing and logistics posture. A 10.6-hour half-life can enable centralized production with tight just-in-time delivery, but it compresses operational windows and raises the bar on supply chain precision, site readiness, and QC turnaround. Dose interval exploration from six weeks down to weekly suggests the program is looking for a therapeutic window that balances potency with salivary gland and marrow tolerability—key hurdles that have constrained alpha-PSMA programs to date.
For sites, this points to escalating nuclear medicine demands: alpha-handling SOPs, shielding and waste protocols, and scheduling discipline to infuse within narrow timeframes. Pharmacy and physics teams will need capacity for rapid release testing and potential same-day deviations if deliveries slip. CROs and sponsors will contend with cross-border radiation licensing, chain-of-custody controls, and harmonized AE capture for xerostomia, cytopenias, and renal effects. Regulators are scrutinizing alpha emitters for off-target dose, and will expect clear PSMA PET-based eligibility criteria, dosimetry rationale, and durable safety readouts. Vendors tied to generator supply, chelation chemistry, and cold kit manufacturing will be a rate-limiter if the signal is positive, and sponsors running parallel actinium-225 PSMA programs will benchmark any efficacy and tolerability head-to-head, at least informally.
At ESMO, the operative questions are granular. What are the PSA50 and radiographic response rates, and how do they vary by dose and interval? Are prior Lu-177–treated patients included, and does activity persist in that context? What are the rates and grades of xerostomia and hematologic toxicity, and can dose intensity be maintained over multiple cycles? Does the program select a single RP2D or a schedule-based strategy, and will Phase 2 move into hormone-sensitive disease with randomization against a recognized control? Equally important is execution: evidence of scalable 212Pb supply, multi-site manufacturing readiness, and consistent labeling yields will indicate whether the program can move beyond single-center feasibility.
If the efficacy and safety profile holds with the expanded cohorts, a randomized Phase 2 in post-Lu-177 mCRPC or earlier lines becomes a credible next step. Risks remain concentrated in isotope supply reliability, inter-site operational variance, and longer-term toxicity characterization. The broader signal for the field is that alpha-PSMA development is transitioning from academic case series to industrial trial infrastructure; success will hinge as much on logistics and reproducibility as on incremental clinical benefit.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
